St. Jude Reference #SJ-16-0029
Hematopoietic Stem Cell (HSC) transplantation is the only curative therapy for many hematologic diseases, as well as a critical life-saving therapy following high dose chemotherapy for many non-hematopoietic cancers. Researchers at St. Jude Children’s Research Hospital have developed a way to enhance HSC transplantation by treating pre-graft cells with silencing constructs for reducing expression of GASP (G-protein coupled receptor Associated Sorting Proteins) family genes, either permanently or transiently to improve the ability of these cells to replenish the hematopoietic system of host organisms. Further, the use of GASP gene silenced umbilical cord blood-derived cells is contemplated for transplantation into HLA mismatched (allogeneic) hosts.
Benefits to this new method include:
Overcoming limitations on the amount of UCB cells required for HSC transplantation in adults.
Hematopoietic Stem Cell (HSC) transplantation, GASP, G-protein coupled receptor Associated Sorting Proteins, GA2
Granted patents or published applications
US Patent application pending, published as 2019/0328791
Related scientific references
Please contact us if you are interested in licensing this technology. Contact: firstname.lastname@example.org
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.